Compare UHS & CRL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | UHS | CRL |
|---|---|---|
| Founded | 1978 | 1947 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Hospital/Nursing Management | Biotechnology: Commercial Physical & Biological Resarch |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.3B | 8.6B |
| IPO Year | 1994 | 1999 |
| Metric | UHS | CRL |
|---|---|---|
| Price | $145.22 | $199.75 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 11 | 12 |
| Target Price | ★ $216.36 | $198.27 |
| AVG Volume (30 Days) | ★ 1.0M | 750.7K |
| Earning Date | 04-27-2026 | 05-07-2026 |
| Dividend Yield | ★ 0.48% | N/A |
| EPS Growth | ★ 37.34 | N/A |
| EPS | ★ 5.65 | N/A |
| Revenue | ★ $17,364,829,000.00 | $1,857,601,000.00 |
| Revenue This Year | $7.67 | N/A |
| Revenue Next Year | $4.99 | $3.04 |
| P/E Ratio | $25.81 | ★ N/A |
| Revenue Growth | 9.71 | ★ 10.48 |
| 52 Week Low | $140.08 | $144.26 |
| 52 Week High | $246.33 | $228.88 |
| Indicator | UHS | CRL |
|---|---|---|
| Relative Strength Index (RSI) | 41.16 | 65.64 |
| Support Level | $140.08 | $193.41 |
| Resistance Level | $148.18 | $228.64 |
| Average True Range (ATR) | 4.06 | 7.12 |
| MACD | 1.03 | 0.54 |
| Stochastic Oscillator | 58.72 | 83.68 |
Universal Health Services Inc offers healthcare services through its behavioral health centers, acute care hospitals, and related outpatient facilities. As of late 2025, the company operated 346 inpatient behavioral health centers, 29 acute care hospitals, and many supportive outpatient facilities. Its operations are concentrated in the U.S, particularly in Nevada (21% of 2025 operating profits), Texas (19%), and California (13%), although it does have some exposure to the UK behavioral health market (6% of 2025 sales) too. While its acute care services account for over 55% of revenue, the behavioral health centers sport higher margins and account for over 55% of pretax profits.
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.